Search Results - "Lassam, N."

Refine Results
  1. 1

    MLK‐3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6 by Tibbles, L. A., Ing, Y. L., Kiefer, F., Chan, J., Iscove, N., Woodgett, J. R., Lassam, N. J.

    Published in The EMBO journal (16-12-1996)
    “…Mixed lineage kinase‐3 (MLK‐3) is a 97 kDa serine/threonine kinase with multiple interaction domains, including a Cdc42 binding motif, but unknown function…”
    Get full text
    Journal Article
  2. 2

    CDKN2A Mutations in Multiple Primary Melanomas by Monzon, Jose, Liu, Ling, Brill, Herbert, Goldstein, Alisa M, Tucker, Margaret A, From, Lynn, McLaughlin, John, Hogg, David, Lassam, Norman J

    Published in The New England journal of medicine (26-03-1998)
    “…Some patients with cancer have one or more subsequent primary tumors of the same histologic subtype. This phenomenon can be explained by the long-term exposure…”
    Get full text
    Journal Article
  3. 3

    Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-Aza-2'-deoxycytidine by WEBER, J, SALGALLER, M, SAMID, D, JOHNSON, B, HERLYN, M, LASSAM, N, TREISMAN, J, ROSENBERG, S. A

    Published in Cancer research (Chicago, Ill.) (01-04-1994)
    “…MAGE-1 is a gene that encodes an antigen on a melanoma cell line that is recognized by cytolytic T-cells. We have used a reverse transcription-polymerase chain…”
    Get full text
    Journal Article
  4. 4

    Overexpression of p53 is a late event in the development of malignant melanoma by LASSAM, N. J, FROM, L, KAHN, H. J

    Published in Cancer research (Chicago, Ill.) (15-05-1993)
    “…Overexpression of the p53 gene product has been observed in a high percentage of malignant melanomas. To evaluate the role of this protein in the development…”
    Get full text
    Journal Article
  5. 5

    HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway by Kiefer, F., Tibbles, L. A., Anafi, M., Janssen, A., Zanke, B. W., Lassam, N., Pawson, T., Woodgett, J. R., Iscove, N. N.

    Published in The EMBO journal (16-12-1996)
    “…In mammalian cells, a specific stress‐activated protein kinase (SAPK/JNK) pathway is activated in response to inflammatory cytokines, injury from heat,…”
    Get full text
    Journal Article
  6. 6

    Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma : results of a phase 1 clinical trial by STEWART, A. K, LASSAM, N. J, ADDISON, C. L, MOEN, R. C, GAULDIE, T, GRAHAM, F. L, QUIRT, I. C, BAILEY, D. J, ROTSTEIN, L. E, KRAJDEN, M, DESSUREAULT, S, GALLINGER, S, CAPPE, D, WAN, Y

    Published in Gene therapy (01-03-1999)
    “…We conducted a phase 1 trial of direct injection of an E1, E3-deleted adenovirus encoding interleukin-2 (AdCAIL-2) into subcutaneous deposits of melanoma or…”
    Get full text
    Journal Article
  7. 7

    Loss of c-kit expression in cultured melanoma cells by Lassam, N, Bickford, S

    Published in Oncogene (01-01-1992)
    “…The proto-oncogene c-kit encodes a receptor tyrosine kinase which has been shown to play a key role in melanocyte development. In this report we asked whether…”
    Get more information
    Journal Article
  8. 8

    CDKN2A mutation in a non‐FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein by Sun, Sophie, Pollock, Pamela M., Liu, Ling, Karimi, Sepideh, Jothy, Serge, Milner, Benedict J., Renwick, Andrew, Lassam, Norman J., Hayward, Nicholas K., Hogg, David, Narod, Steven A., Foulkes, William D.

    Published in International journal of cancer (14-11-1997)
    “…The CDKN2A gene encodes p16 (CDKN2A), a cell‐cycle inhibitor protein which prevents inappropriate cell cycling and, hence, proliferation. Germ‐line mutations…”
    Get full text
    Journal Article
  9. 9

    MLK-3: identification of a widely-expressed protein kinase bearing an SH3 domain and a leucine zipper-basic region domain by Ing, Y L, Leung, I W, Heng, H H, Tsui, L C, Lassam, N J

    Published in Oncogene (01-06-1994)
    “…We have identified a novel protein kinase, designated MLK-3, from human thymus using RT-PCR and cDNA library screening. The deduced open reading frame, derived…”
    Get more information
    Journal Article
  10. 10

    Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation by Lassam, N, Jay, G

    Published in The Journal of immunology (1950) (01-12-1989)
    “…The oncogenic potential of some transformed cell lines has been shown in animal tumor models to be the direct result of MHC class I mRNA suppression. Rodent…”
    Get full text
    Journal Article
  11. 11

    Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations by Lal, Geeta, Liu, Ling, Hogg, David, Lassam, Norman J., Redston, Mark S., Gallinger, Steven

    Published in Genes chromosomes & cancer (01-04-2000)
    “…Germline mutations of the CDKN2A tumor suppressor gene have been identified in melanoma kindreds linked to 9p21, and pancreatic adenocarcinoma is the second…”
    Get full text
    Journal Article
  12. 12

    Fine mapping of the MLK-3 gene within 11q13 and its exclusion as the MEN1 susceptibility gene by LASSAM, N. J, LIN, Z, SHENNAN, M. G, COURSEAUX, A, TEH, B. T, GAUDRAY, P, LARSSON, C

    Published in Human genetics (01-06-1997)
    “…MLK-3 kinase is a widely expressed serine/ threonine kinase that bears multiple protein interaction domains and regulates signals mediated by the…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Protein kinases in normal and transformed melanocytes by Quong, R Y, Bickford, S T, Ing, Y L, Terman, B, Herlyn, M, Lassam, N J

    Published in Melanoma research (01-10-1994)
    “…Aberrant function of protein kinases has been implicated in the development of melanoma. In an effort to define the molecular events involved in initiation and…”
    Get more information
    Journal Article
  15. 15

    The mouse homologs of RELA and MLK3 are located within a 120-kb fragment on chromosome 19 by Fernandes, M, Poirier, C, Lassam, N J, Larsson, C, Guénet, J, Gaudray, P, Carle, G F

    Published in Mammalian genome (01-07-1997)
    “…Recent advances in the identification of a large collection of polymorphic genetic markers and unique probes have yielded respectively detailed genetic and…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma by Hogg, D, Brill, H, Liu, L, Monzon, J, Summers, A, From, L, Lassam, N J

    Published in Journal of cutaneous medicine and surgery (01-01-1998)
    “…Approximately 8 to 12% of melanoma appears to be inherited in an autosomal dominant form. Although most early stage melanomas can be treated successfully by…”
    Get more information
    Journal Article
  18. 18
  19. 19

    VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor by Terman, B, Khandke, L, Dougher-Vermazan, M, Maglione, D, Lassam, N J, Gospodarowicz, D, Persico, M G, Böhlen, P, Eisinger, M

    “…Vascular endothelial growth factor (VEGF) is an angiogenic growth factor which binds to two structurally related tyrosine kinase receptors denoted KDR and…”
    Get more information
    Journal Article
  20. 20

    Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma by Hogg, David, Liu, Ling, Dilworth, David, Gao, Luzhang, Monzon, Jose, Summers, Ann, Lassam, Norman

    Published in Nature genetics (01-01-1999)
    “…Approximately 8-12% of melanoma is inherited in an autosomal dominant fashion with variable penetrance. A chromosome 9p21 locus has been linked to this disease…”
    Get full text
    Journal Article